Drug Trial Radar · NCT07812116
A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Oct 19, 2026
Primary completion
Jun 16, 2028
Study completion Nov 8, 2030
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Teva Branded Pharmaceutical Products R&D LLC
- First posted
- Sep 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, Phase 2b, 3-arm, double-blind, randomized, multicenter, multinational, placebo-controlled, dose-ranging study to evaluate the efficacy and the safety of different doses of duvakitug in adult participants with moderate to severe hidradenitis suppurativa. Study details include: * The study duration will be up to 145 weeks , including a 4-week screening period, a 16-week initial double-blind treatment period, a 24-week active blinded extension period, a 96-week long-term extension period and a 5-week follow-up period. * The treatment duration will be up to 40 weeks for the participants who will stop after the active blinded extension period and up to 136 weeks for the participants who will continue in the long-term extension period. * The number of visits will be up to 23 for the participants who will stop after the active blinded extension period and up to 71 for the participants who will continue in the long-term extension period.
Conditions
- Hidradenitis
Interventions
DuvakitugDrug
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
PlaceboDrug
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Time frame: At Week 16
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Cahaba Dermatology & Skin Health Center- Site Number : 8400004
Birmingham, Alabama · Recruiting
Florida International Research Center- Site Number : 8400002
Miami, Florida · Recruiting
Investigational Site Number : 1240002
Peterborough, Ontario, Canada · Recruiting
Investigational Site Number : 1240006
Richmond Hill, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.